Year-end Sale % OFF 
Abstract
Background Pulmonary hypertension (PH) due to vasoconstriction and occlusion of the pulmonary microvasculature is a characteristic feature of the acute respiratory distress syndrome (ARDS). Inhaled nitric oxide (NO) selectively dilates the pulmonary vasculature by activating soluble guanylate cylase (sGC). Bay 41-2272 a novel sGC stimulator not only activates sGC NO independently, but also leads to synergistic effects when combined with NO. Because contradictory results of a number of experimental studies dealing with the effects of iNO in acute lung injury and the uncertain efficacy of iNO in the treatment of ARDS, we evaluated the effects of iNO and BAY 41-2272 in a model of acute lung injury. METHODS: Acute lung injury (ALI) was induced by i.v. injection of oleic acid (OA). In the first treatment group iNO (2 ppm) was administered continuously after ALI. In the second group, BAY 41-2272 (100 μg/kg) was infused for 10 min directly after injection of OA. In the third group, iNO and BAY 412272 were combined.
Highlights
Pulmonary hypertension (PH) due to vasoconstriction and occlusion of the pulmonary microvasculature is a characteristic feature of the acute respiratory distress syndrome (ARDS)
Bay 41-2272 a novel soluble guanylate cylase (sGC) stimulator activates sGC nitric oxide (NO) independently, and leads to synergistic effects when combined with NO
Because contradictory results of a number of experimental studies dealing with the effects of iNO in acute lung injury and the uncertain efficacy of iNO in the treatment of ARDS, we evaluated the effects of iNO and BAY 41-2272 in a model of acute lung injury
Summary
Andreas Weidenbach*1, Johannes-Peter Stasch, Hossein Ardeschir Ghofrani, Norbert Weissmann, Friedrich Grimminger, Werner Seeger and Ralph Theo Schermuly. Address: 1Center for Internal Medicine, Medical Clinic II, University Hospital of the Justus-Liebig-University Giessen, Klinikstrasse 36, 35392 Giessen, Germany and 2Institute of Cardiovascular Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany. Published: 16 June 2005 BMC Pharmacology 2005, 5(Suppl 1):P61 doi:10.1186/1471-2210-5-S1-P61. 2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications Meeting abstracts
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
